杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/01/17 | 1,843 | 1,843 | 1,815 | 1,826 | -9 | -0.5% | 29,900 |
| 2022/01/14 | 1,826 | 1,835 | 1,811 | 1,835 | +8 | +0.4% | 77,300 |
| 2022/01/13 | 1,820 | 1,831 | 1,813 | 1,827 | +5 | +0.3% | 70,500 |
| 2022/01/12 | 1,815 | 1,838 | 1,810 | 1,822 | +14 | +0.8% | 54,700 |
| 2022/01/11 | 1,813 | 1,813 | 1,786 | 1,808 | +9 | +0.5% | 52,700 |
| 2022/01/07 | 1,801 | 1,812 | 1,781 | 1,799 | -3 | -0.2% | 71,200 |
| 2022/01/06 | 1,820 | 1,834 | 1,799 | 1,802 | -29 | -1.6% | 66,100 |
| 2022/01/05 | 1,849 | 1,849 | 1,820 | 1,831 | -7 | -0.4% | 75,900 |
| 2022/01/04 | 1,842 | 1,848 | 1,826 | 1,838 | -8 | -0.4% | 78,700 |
| 2021/12/30 | 1,845 | 1,850 | 1,840 | 1,846 | +1 | +0.1% | 51,100 |
| 2021/12/29 | 1,838 | 1,857 | 1,829 | 1,845 | ±0 | ±0% | 75,800 |
| 2021/12/28 | 1,828 | 1,845 | 1,816 | 1,845 | +22 | +1.2% | 104,400 |
| 2021/12/27 | 1,815 | 1,824 | 1,791 | 1,823 | +12 | +0.7% | 68,500 |
| 2021/12/24 | 1,813 | 1,818 | 1,800 | 1,811 | +11 | +0.6% | 78,100 |
| 2021/12/23 | 1,810 | 1,810 | 1,787 | 1,800 | -10 | -0.6% | 78,900 |
| 2021/12/22 | 1,798 | 1,810 | 1,790 | 1,810 | +21 | +1.2% | 97,600 |
| 2021/12/21 | 1,796 | 1,799 | 1,782 | 1,789 | +15 | +0.8% | 78,400 |
| 2021/12/20 | 1,783 | 1,794 | 1,773 | 1,774 | -25 | -1.4% | 63,700 |
| 2021/12/17 | 1,797 | 1,808 | 1,786 | 1,799 | -7 | -0.4% | 131,800 |
| 2021/12/16 | 1,815 | 1,816 | 1,790 | 1,806 | +14 | +0.8% | 84,700 |
| 2021/12/15 | 1,790 | 1,803 | 1,783 | 1,792 | -7 | -0.4% | 62,300 |
| 2021/12/14 | 1,782 | 1,803 | 1,777 | 1,799 | +34 | +1.9% | 98,600 |
| 2021/12/13 | 1,800 | 1,800 | 1,761 | 1,765 | -28 | -1.6% | 64,400 |
| 2021/12/10 | 1,789 | 1,804 | 1,776 | 1,793 | +4 | +0.2% | 131,900 |
| 2021/12/09 | 1,804 | 1,809 | 1,787 | 1,789 | -6 | -0.3% | 208,400 |
| 2021/12/08 | 1,783 | 1,798 | 1,773 | 1,795 | +13 | +0.7% | 149,800 |
| 2021/12/07 | 1,743 | 1,783 | 1,741 | 1,782 | +52 | +3% | 113,200 |
| 2021/12/06 | 1,737 | 1,755 | 1,729 | 1,730 | -12 | -0.7% | 110,700 |
| 2021/12/03 | 1,692 | 1,742 | 1,685 | 1,742 | +59 | +3.5% | 124,000 |
| 2021/12/02 | 1,663 | 1,693 | 1,663 | 1,683 | +11 | +0.7% | 96,100 |
| 2021/12/01 | 1,675 | 1,675 | 1,662 | 1,672 | -16 | -0.9% | 100,700 |
| 2021/11/30 | 1,689 | 1,721 | 1,683 | 1,688 | -12 | -0.7% | 198,800 |
| 2021/11/29 | 1,692 | 1,716 | 1,692 | 1,700 | -8 | -0.5% | 86,900 |
| 2021/11/26 | 1,716 | 1,716 | 1,693 | 1,708 | -12 | -0.7% | 86,000 |
| 2021/11/25 | 1,713 | 1,720 | 1,700 | 1,720 | ±0 | ±0% | 104,600 |
| 2021/11/24 | 1,730 | 1,748 | 1,716 | 1,720 | -9 | -0.5% | 75,800 |
| 2021/11/22 | 1,719 | 1,730 | 1,707 | 1,729 | -1 | -0.1% | 51,700 |
| 2021/11/19 | 1,736 | 1,742 | 1,720 | 1,730 | -12 | -0.7% | 69,700 |
| 2021/11/18 | 1,746 | 1,746 | 1,718 | 1,742 | -13 | -0.7% | 106,100 |
| 2021/11/17 | 1,785 | 1,785 | 1,753 | 1,755 | -30 | -1.7% | 69,100 |
| 2021/11/16 | 1,797 | 1,809 | 1,779 | 1,785 | -21 | -1.2% | 79,700 |
| 2021/11/15 | 1,818 | 1,820 | 1,796 | 1,806 | +3 | +0.2% | 66,500 |
| 2021/11/12 | 1,768 | 1,803 | 1,768 | 1,803 | +27 | +1.5% | 79,400 |
| 2021/11/11 | 1,790 | 1,790 | 1,772 | 1,776 | -13 | -0.7% | 63,700 |
| 2021/11/10 | 1,830 | 1,830 | 1,783 | 1,789 | -17 | -0.9% | 75,300 |
| 2021/11/09 | 1,761 | 1,809 | 1,760 | 1,806 | +45 | +2.6% | 132,200 |
| 2021/11/08 | 1,775 | 1,786 | 1,761 | 1,761 | -13 | -0.7% | 75,900 |
| 2021/11/05 | 1,778 | 1,780 | 1,765 | 1,774 | -16 | -0.9% | 70,800 |
| 2021/11/04 | 1,795 | 1,795 | 1,774 | 1,790 | +7 | +0.4% | 75,700 |
| 2021/11/02 | 1,781 | 1,798 | 1,773 | 1,783 | -17 | -0.9% | 83,600 |
701～
750
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ＪＣＲファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| 栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
